 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SAN MATEO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT Research Report), with a price tar...

Promising Lipidomic Data and Financial Stability Bolsters Buy Recommendation for Sagimet Biosciences

On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024 Two abstracts, including late-breaker, accepted at the American...

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting  2023

SAN MATEO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting  2023

SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that...

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Sagimet Biosciences management to meet virtually with Piper Sandler

SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Market Cap	$77.59M
Volume (M)	81,090.00
52-Wk High	$18.33
52-Wk Low	$2.13

Current Price	$3.63
Prev Close	$4.04
Open	$4.04
Dividend Yield	N/A
50-Day Moving Average	$4.58
Beta	0.00
Avg. Volume	150,411.29
PE Ratio	N/A

52-Week High	$18.33
52-Week Low	$2.13
Market Capitalization	$77.59M
EPS	N/A
Price to Book	0.79
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

SGMT Sagimet Biosciences Inc

About

Feed

News

Fundamentals